Latest Global Expansion News

Advanced Braking Technology Ltd reports a robust Q2 FY26 with a 34% increase in product sales revenue and a 191% jump in net profit before tax, underpinned by strong international expansion and domestic contract wins.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

AdAlta Limited and its subsidiary AdCella have partnered with Shanghai Cell Therapy Group to co-develop a pioneering CAR-T cancer therapy targeting solid tumours outside China. This collaboration aims to bring a novel, armored immunotherapy with promising clinical results to global markets.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

RocketBoots Limited has secured a landmark five-year contract with a major multinational retailer, boosting its annual recurring revenue by over tenfold and marking a pivotal step in its global expansion.

BetMakers Technology Group has secured a multi-year deal with Stake.com to provide its comprehensive RaceOdds+ wagering platform, supporting Stake’s ambitious global horse racing growth plans.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Acusensus Limited has announced a $30 million equity placement to bolster its balance sheet, alongside winning a landmark $34 million contract in Connecticut, marking a significant step in its US expansion. The company also reported multiple contract expansions in Australia and a new debt facility to support its growth ambitions.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Flight Centre Travel Group has agreed to acquire UK online cruise leader Iglu for £122 million, boosting its cruise sector footprint and upgrading FY26 profit guidance. The deal promises immediate earnings accretion and strategic expansion into key global markets.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.